Sterneck Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $892K | Sell |
31,755
-900
| -3% | -$24K | 0.4% | 37 |
|
|
2025
Q4 | $813K | Sell |
32,655
-684
| -2% | -$17.2K | 0.37% | 39 |
|
|
2025
Q3 | $849K | Buy |
33,339
+709
| +2% | +$17.5K | 0.4% | 39 |
|
|
2025
Q2 | $791K | Hold |
32,630
| – | – | 0.4% | 41 |
|
|
2025
Q1 | $827K | Hold |
32,630
| – | – | 0.45% | 39 |
|
|
2024
Q4 | $866K | Buy |
32,630
+14,107
| +76% | +$383K | 0.47% | 37 |
|
|
2024
Q3 | $536K | Buy |
18,523
+3,304
| +22% | +$96.4K | 0.29% | 43 |
|
|
2024
Q2 | $426K | Buy |
15,219
+602
| +4% | +$16.6K | 0.24% | 55 |
|
|
2024
Q1 | $406K | Buy |
14,617
+426
| +3% | +$11.8K | 0.24% | 57 |
|
|
2023
Q4 | $409K | Sell |
14,191
-1,011
| -7% | -$30.6K | 0.26% | 61 |
|
|
2023
Q3 | $504K | Sell |
15,202
-900
| -6% | -$31.8K | 0.34% | 53 |
|
|
2023
Q2 | $591K | Hold |
16,102
| – | – | 0.36% | 53 |
|
|
2023
Q1 | $657K | Buy |
16,102
+1,600
| +11% | +$69.1K | 0.41% | 52 |
|
|
2022
Q4 | $743K | Sell |
14,502
-1,641
| -10% | -$78.7K | 0.49% | 48 |
|
|
2022
Q3 | $706K | Buy |
16,143
+3,039
| +23% | +$148K | 0.5% | 42 |
|
|
2022
Q2 | $687K | Sell |
13,104
-1,200
| -8% | -$61.2K | 0.46% | 47 |
|
|
2022
Q1 | $741K | Buy |
14,304
+2,908
| +26% | +$151K | 0.44% | 45 |
|
|
2021
Q4 | $673K | Sell |
11,396
-68
| -0.6% | -$3.37K | 0.4% | 50 |
|
|
2021
Q3 | $493K | Sell |
11,464
-1,500
| -12% | -$66.5K | 0.31% | 53 |
|
|
2021
Q2 | $563K | Hold |
12,964
| – | – | 0.35% | 51 |
|
|
2021
Q1 | $470K | Buy |
12,964
+3,700
| +40% | +$131K | 0.33% | 47 |
|
|
2020
Q4 | $341K | Buy |
9,264
+1,502
| +19% | +$55.1K | 0.26% | 53 |
|
|
2020
Q3 | $270K | Hold |
7,762
| – | – | 0.23% | 56 |
|
|
2020
Q2 | $241K | Sell |
7,762
-1,212
| -14% | -$41.2K | 0.23% | 62 |
|
|
2020
Q1 | $278K | Buy |
8,974
+1,581
| +21% | +$53.9K | 0.28% | 63 |
|
|
2019
Q4 | $275K | Sell |
7,393
-82
| -1% | -$2.92K | 0.22% | 76 |
|
|
2019
Q3 | $255K | Sell |
7,475
-843
| -10% | -$30.7K | 0.23% | 68 |
|
|
2019
Q2 | $342K | Hold |
8,318
| – | – | 0.3% | 58 |
|
|
2019
Q1 | $335K | Hold |
8,318
| – | – | 0.29% | 57 |
|
|
2018
Q4 | $344K | Sell |
8,318
-61
| -0.7% | -$2.53K | 0.33% | 56 |
|
|
2018
Q3 | $350K | Sell |
8,379
-2,616
| -24% | -$101K | 0.25% | 69 |
|
|
2018
Q2 | $378K | Hold |
10,995
| – | – | 0.26% | 68 |
|
|
2018
Q1 | $370K | Sell |
10,995
-31,908
| -74% | -$1.1M | 0.22% | 86 |
|
|
2017
Q4 | $1.47M | Sell |
42,903
-3,711
| -8% | -$127K | 0.88% | 41 |
|
|
2017
Q3 | $1.58M | Sell |
46,614
-2,910
| -6% | -$93.5K | 0.91% | 39 |
|
|
2017
Q2 | $1.58M | Buy |
49,524
+493
| +1% | +$15.5K | 0.94% | 37 |
|
|
2017
Q1 | $1.59M | Sell |
49,031
-27,349
| -36% | -$862K | 0.95% | 36 |
|
|
2016
Q4 | $2.35M | Sell |
76,380
-5,831
| -7% | -$178K | 1.51% | 23 |
|
|
2016
Q3 | $2.64M | Sell |
82,211
-16,932
| -17% | -$566K | 1.76% | 14 |
|
|
2016
Q2 | $3.31M | Sell |
99,143
-2,857
| -3% | -$91.2K | 2.2% | 11 |
|
|
2016
Q1 | $2.87M | Buy |
102,000
+38,587
| +61% | +$1.1M | 2.02% | 13 |
|
|
2015
Q4 | $1.94M | Sell |
63,413
-28,132
| -31% | -$885K | 1.24% | 26 |
|
|
2015
Q3 | $2.73M | Sell |
91,545
-12,700
| -12% | -$407K | 1.79% | 16 |
|
|
2015
Q2 | $3.32M | Sell |
104,245
-339
| -0.3% | -$11K | 1.82% | 15 |
|
|
2015
Q1 | $3.45M | Sell |
104,584
-8,845
| -8% | -$281K | 1.86% | 17 |
|
|
2014
Q4 | $3.35M | Buy |
113,429
+6,589
| +6% | +$189K | 1.99% | 16 |
|
|
2014
Q3 | $3M | Buy |
106,840
+21,503
| +25% | +$604K | 1.8% | 13 |
|
|
2014
Q2 | $2.4M | Sell |
85,337
-5,554
| -6% | -$158K | 1.4% | 24 |
|
|
2014
Q1 | $2.77M | Sell |
90,891
-2,519
| -3% | -$75.1K | 1.5% | 25 |
|
|
2013
Q4 | $2.71M | Sell |
93,410
-3,400
| -4% | -$99K | 1.65% | 19 |
|
|
2013
Q3 | $2.64M | Sell |
96,810
-1,798
| -2% | -$48.9K | 1.67% | 18 |
|
|
2013
Q2 | $2.62M | Buy |
+98,608
| New | +$2.72M | 1.65% | 19 |
|
Other funds holding PFE
VCM
VPM
Sterneck Capital Management's PFE Position: Q1 2026 in Review
Sterneck Capital Management reduced its Pfizer (PFE) stake by 2.8% in Q1 2026, selling an estimated $24K and leaving 31,755 shares worth $892K. The position accounts for 0.4% of the portfolio, ranked #37.
Sterneck Capital Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $3.45M in Q1 2015. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Sterneck Capital Management held 31,755 shares of Pfizer worth $892K as of Q1 2026.
- Sterneck Capital Management sold 900 Pfizer shares in Q1 2026, an estimated $24K.
- Pfizer made up 0.4% of Sterneck Capital Management's portfolio in Q1 2026, its #37 holding.
- Sterneck Capital Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
- Sterneck Capital Management's Pfizer position peaked at $3.45M in Q1 2015.
- 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Sterneck Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.